ChemicalBook CAS DataBase List Evinacumab

Evinacumab

Product NameEvinacumab
CAS1446419-85-7
CBNumberCB78080922
MW0
MOL FileMol file
MSDS FileSDS

Chemical Properties

form	Liquid
color	Colorless to light yellow
FDA UNII	T8B2ORP1DW

Evinacumab Price

Product number	Packaging	Price	Product description	Buy
ChemScene CS-0612943	1mg	$314	Evinacumab 99.24%	Buy
ChemScene CS-0612943	5mg	$1029	Evinacumab 99.24%	Buy
Biorbyt Ltd orb1290200	100μg	$180	Evinacumab >95%	Buy
Biorbyt Ltd orb1290200	1mg	$700	Evinacumab >95%	Buy
aablocks AA02A4JT	1mg	$932	Evinacumab ≥95%(SDS-PAGE&SEC-HPLC)	Buy

Evinacumab Chemical Properties,Usage,Production

Uses

Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia[1].

in vivo

Evinacumab (REGN1500) (10 mg/kg; s.c.; single) lowers serum TGs in normolipidemic C57Bl/6 mice and increases postheparin plasma LPL activity^[1].
Evinacumab (25 mg/kg; s.c.; once weekly for 8 weeks) lowers serum TG and cholesterol levels in dyslipidemic C57Bl/6 mice^[1].
Evinacumab (10 mg/kg; s.c.; single) lowers serum HDL-C by an EL-dependent mechanism in Lipg^-/- mice^[1].

Animal Model:	Male C57Bl/6 mice (8-week-old)^[1].
Dosage:	10 mg/kg
Administration:	Subcutaneous injection, single.
Result:	Caused a rapid reduction in TG levels with the maximal mean level of serum TG 55% lower than control group, and reduced 26% levels of TC. Significantly reduced VLDL-TG, VLDL-cholesterol, and HDL-C levels. Increased postheparin plasma LPL and improved lipid tolerance.

Animal Model:	Male C57Bl/6 mice (8-week-old; on a high-fat high-cholesterol diet)^[1].
Dosage:	25 mg/kg
Administration:	Subcutaneous injection, once weekly for 8 weeks.
Result:	Led to a marked and sustained reduction in circulating TG levels (up to 53%). Significantly reduced levels of TC (up to 35%) and LDL-C (up to 45%).

Animal Model:	Lipg^-/- mice^[1].
Dosage:	10 mg/kg
Administration:	Subcutaneous injection, single.
Result:	Blocked the inhibitory action of ANGPTL3 on EL with an IC₅₀ value of 96 nM.

References

[1] Gusarova V, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015 Jul;56(7):1308-17. DOI:10.1194/jlr.M054890

Preparation Products And Raw materials

Evinacumab Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Shanghai YuanYe Biotechnology Co., Ltd.	18916372613	yanzihan@shyuanye.com	China	87240	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	7996	62
Chemleader Biomedical Co., Limited.	021-58180488	sales@MedChemLeader.com	China	1004	58
BOC Sciences	16314854226; +8616314854226	inquiry@bocsci.com	United States	19852	58
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1577	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10302	58
Beijing Jin Ming Biotechnology Co., Ltd.	010-60605840	psaitong@jm-bio.com	China	27626	58
Biolab Reagents	027-65279366 18108604356	products@biolabreagent.com	China	9864	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	7284	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11963	58

1446419-85-7, EvinacumabRelated Search

Send Inquiry